EU Drug Markets Report 2019


The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol.

A more recent version of this publication is now available: EU Drug Markets: In-depth analysis

The analysis presented in this report spans numerous topics such as the links between drugs and other crimes, the licit economy and society more generally as well as the processes and players involved in the trade, from production and trafficking to distribution. Taking an evidence-based approach, the report reviews the markets for heroin, cocaine, cannabis, amphetamine, methamphetamine, MDMA and new psychoactive substances. It also provides action points to inform policy development at EU and national level. This publication is an essential reference for law enforcement professionals, policymakers, the academic community and indeed for anyone seeking up-to-date information and analysis on drug markets in Europe.

Corrigendum: the original PDF file was updated on 9 January 2020 with the following corrections:
p. 65 (on the fourth line ‘increased’ rather than ‘decreased’).
p.107 (quantity of heroin seized),
p. 153 (quantity of amphetamines seized).

Download as PDF

Table of contents

Table of contents

  • Foreword
  • Introduction
  • Acknowledgements
  • Explanatory note on data
  • Executive summary
  • PART I: Impacts and drivers of drug markets
    • CHAPTER 1: Impacts and consequences of drug markets
    • CHAPTER 2: Drivers and facilitators of drug markets
  • PART II: Main drug markets in the EU
    • CHAPTER 3: Cannabis
    • CHAPTER 4: Heroin and other opioids
    • CHAPTER 5: Cocaine
    • CHAPTER 6: Amphetamine, MDMA and methamphetamine
    • CHAPTER 7: New psychoactive substances
  • PART III: Responding to drug markets
    • CHAPTER 8: Policy instruments and structures
    • CHAPTER 9: Targeting operational responses to drug markets and associated criminality
  • References
  • Abbreviations
  • Annex: Principal areas of EU legislation linked to drug supply reduction
  • Index